Literature DB >> 18413264

Genetic modeling of Ras-induced human rhabdomyosarcoma.

Corinne M Linardic1, Christopher M Counter.   

Abstract

Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Historically, rhabdomyosarcoma has been studied by the manipulation of human cell lines derived from primary rhabdomyosarcoma tumor tissue adapted to grow in culture. Recently, mouse models have been added to the arsenal of tools to study this disease in vivo. However, given the emerging understanding of the genetic variability and mutability of human tumor-derived cell lines, and the existing differences between human and murine tumorigenesis, we sought to uniformly dissect the genetic events required to generate rhabdomyosarcoma from primary human skeletal muscle precursors. To this end, primary human skeletal muscle cells were transformed with defined genetic elements to corrupt the p53, Rb, Myc, telomerase, and Ras pathways, resulting in cells that, when assayed as subcutaneous xenografts in immunocompromised mice, formed tumors indistinguishable at the immunohistochemical level from the embryonal histologic variant of rhabdomyosarcoma. This chapter will discuss the techniques used to transform primary human skeletal muscle cells, the assays used to verify expression of the ectopically expressed genetic elements, and the methods used to evaluate the tumorigenic capacity of the resulting cell lines.

Entities:  

Mesh:

Year:  2008        PMID: 18413264      PMCID: PMC2782627          DOI: 10.1016/S0076-6879(07)38028-2

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  17 in total

1.  Species- and cell type-specific requirements for cellular transformation.

Authors:  Annapoorni Rangarajan; Sue J Hong; Annie Gifford; Robert A Weinberg
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

2.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

3.  Correction of Sanfilippo A skin fibroblasts by retroviral vector-mediated gene transfer.

Authors:  J Bielicki; J J Hopwood; D S Anson
Journal:  Hum Gene Ther       Date:  1996-10-20       Impact factor: 5.695

4.  A network of genetic events sufficient to convert normal human cells to a tumorigenic state.

Authors:  S DiSean Kendall; Corinne M Linardic; Stacey J Adam; Christopher M Counter
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

5.  An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.

Authors:  Raffaella A Morotti; Kathleen K Nicol; David M Parham; Lisa A Teot; Julie Moore; John Hayes; William Meyer; Stephen J Qualman
Journal:  Am J Surg Pathol       Date:  2006-08       Impact factor: 6.394

Review 6.  Tumorigenesis in neurofibromatosis: new insights and potential therapies.

Authors:  N Reed; D H Gutmann
Journal:  Trends Mol Med       Date:  2001-04       Impact factor: 11.951

Review 7.  Molecular pathogenesis of rhabdomyosarcoma.

Authors:  Shujuan J Xia; Joseph G Pressey; Frederic G Barr
Journal:  Cancer Biol Ther       Date:  2002 Mar-Apr       Impact factor: 4.742

8.  Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.

Authors:  Patrizia Nanni; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Annalisa Astolfi; Lorena Landuzzi; Emma Di Carlo; Manuela Iezzi; Piero Musiani; Pier-Luigi Lollini
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

9.  Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

Authors:  Richard Sharp; Juan A Recio; Chamelli Jhappan; Toshiyuki Otsuka; Shiquan Liu; Yanlin Yu; Wenjing Liu; Miriam Anver; Fariba Navid; Lee J Helman; Ronald A DePinho; Glenn Merlino
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

Review 10.  Distinct requirements for Ras oncogenesis in human versus mouse cells.

Authors:  Nesrin M Hamad; Joel H Elconin; Antoine E Karnoub; Wenli Bai; Jeremy N Rich; Robert T Abraham; Channing J Der; Christopher M Counter
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

View more
  4 in total

Review 1.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

2.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

3.  Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent.

Authors:  Michael J Morgan; Graciela Gamez; Christina Menke; Ariel Hernandez; Jacqueline Thorburn; Freddi Gidan; Leah Staskiewicz; Shellie Morgan; Christopher Cummings; Paola Maycotte; Andrew Thorburn
Journal:  Autophagy       Date:  2014-08-13       Impact factor: 16.016

4.  MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.

Authors:  Hui-jie Huang; Jun Liu; Hu Hua; San-en Li; Jin Zhao; Shen Yue; Ting-ting Yu; Yu-cui Jin; Steven Y Cheng
Journal:  Oncotarget       Date:  2014-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.